Tranexamic acid is a useful first-line treatment for bleeding episodes in patients with Von Willebrand disease, particularly for mucosal bleeding such as nosebleeds, dental procedures, or heavy menstrual bleeding. It works by inhibiting fibrinolysis, helping stabilize clots and prevent premature breakdown of clots. The medication can be taken in several forms, including oral tablets, intravenous (IV) formulations, and topical preparations such as mouthwash or soaked gauze for dental or surgical bleeding. Because it is relatively inexpensive, easy to use, and generally well tolerated, it is often used early before considering factor replacement therapy. Overall, tranexamic acid is a practical and effective option for managing mild bleeding episodes in patients with von Willebrand disease.

Lysteda is a common first-line option for managing von Willebrand disease, particularly in cases linked to low VWF levels, such as those with type O blood. It offers an effective, non-intravenous alternative to Humate-P.